(Charlottetown, PE, June 2, 2016) Neurodyn Life Sciences will take part in the BIO International Convention from June 4 to 9 in San Francisco, California. It’s the largest annual meeting and exhibition for the biotechnology industry in the world. Neurodyn will participate alongside a delegation of bioscience-based companies from Atlantic Canada, led by the Atlantic Canada Bio-Industries Alliance (ACBA).

The company intends to update potential co-development and licensing partners on its clinical-stage Alzheimer’s disease drug candidate, Memogain, and carry-out a series of meetings with potential collaborators on its neuropathic pain program.

“We are eager to once again participate in BIO 2016,” says Ken Cawkell, CEO of Neurodyn. “This event enables our company to showcase our unique technologies and gain exposure for research and commercialization opportunities that are critical to our development programs.”

Neurodyn’s business development and scientific teams will participate in one-on-one partnering meetings, an Atlantic Canadian Bio-Partnering breakfast, and other networking mixers throughout the week.

About Neurodyn:  Neurodyn (www.neurodyn.ca) is a Canadian biotechnology company focused on identifying, validating and developing natural compounds into both prescription drugs and natural products for the early treatment of neurological diseases. Through its offices in Charlottetown, Halifax, and Germany, Neurodyn manages prescription drug and natural health product commercialization as well as subsidiaries in fine chemicals & medicinal chemistry and animal modeling of neurological disease.


Mr. Kenneth Cawkell, Chief Executive Officer

kcawkell@neurodyn.ca  | 1.604.619.0990

Dr. Denis Kay, Chief Scientific Officer

dgkay@neurodyn.ca  | 1.902.314.0776

Mr. Robert Cervelli, Executive Director

cerveli@neurodyn.ca  | 1.902.222.4391